NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis → Digitizing the $11T commodities sector with one tiny stock (From Resource Stock Digest) (Ad) Free VIR Stock Alerts $10.72 +0.17 (+1.61%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$10.60▼$10.8850-Day Range$7.63▼$11.3752-Week Range$7.61▼$27.48Volume417,662 shsAverage Volume1.01 million shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$33.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside213.2% Upside$33.57 Price TargetShort InterestBearish6.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 13 Articles This WeekInsider TradingSelling Shares$777,197 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.42) to ($3.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector588th out of 931 stocksBiological Products, Except Diagnostic Industry94th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.63% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 14.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 3.1 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search Interest8 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $777,197.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.42) to ($3.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Resource Stock DigestDigitizing the $11T commodities sector with one tiny stockOne tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. It’s an opportunity that likely won’t stay at these levels for long About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesMay 26 at 3:20 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Earns Buy Rating from HC WainwrightMay 25 at 2:46 AM | americanbankingnews.comHead to Head Review: Iovance Biotherapeutics (NASDAQ:IOVA) vs. Vir Biotechnology (NASDAQ:VIR)May 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program ProspectsMay 24, 2024 | markets.businessinsider.comEvaluating Vir Biotechnology: Insights From 5 Financial AnalystsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial ResultsMay 23, 2024 | finance.yahoo.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 23, 2024 | businesswire.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 22, 2024 | finance.yahoo.comMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024May 21, 2024 | businesswire.comVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024May 13, 2024 | prnewswire.comBrii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesMay 8, 2024 | finance.yahoo.comAnalysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) EstimatesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical PipelineMay 7, 2024 | markets.businessinsider.comDeep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | seekingalpha.comVir Biotechnology Provides Some Hope For Its Beleaguered ShareholdersMay 3, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comQ1 2024 Vir Biotechnology Inc Earnings CallMay 2, 2024 | investorplace.comVIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024May 2, 2024 | msn.comVir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67MMay 2, 2024 | businesswire.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comVir Biotechnology earnings preview: what Wall Street is expectingApril 30, 2024 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024April 28, 2024 | finance.yahoo.comWith 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backingSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/28/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$33.57 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+218.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-677.69% Pretax Margin-690.97% Return on Equity-32.58% Return on Assets-26.97% Debt Debt-to-Equity RatioN/A Current Ratio12.90 Quick Ratio12.90 Sales & Book Value Annual Sales$86.18 million Price / Sales16.66 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.89Miscellaneous Outstanding Shares136,060,000Free Float114,834,000Market Cap$1.44 billion OptionableOptionable Beta0.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Marianne De Backer M.B.A. (Age 55)M.Sc., Ph.D., CEO & Director Comp: $4.47MMr. Sung H. Lee (Age 54)Executive VP & CFO Comp: $968.45kDr. Ann M. Hanly Ph.D. (Age 54)Executive VP & Chief Technology Officer Comp: $896.07kDr. Jeff Calcagno M.D. (Age 63)Executive VP & Chief Business Officer Comp: $860.49kDr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorDr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsAllogene TherapeuticsNASDAQ:ALLOFate TherapeuticsNASDAQ:FATEReplimune GroupNASDAQ:REPLbluebird bioNASDAQ:BLUEChina Biologic ProductsNASDAQ:CBPOView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 34,750 shares on 5/17/2024Ownership: 0.026%Comerica BankSold 2,990 shares on 5/17/2024Ownership: 0.024%Jacobs Levy Equity Management Inc.Bought 16,615 shares on 5/16/2024Ownership: 0.228%California State Teachers Retirement SystemSold 4,393 shares on 5/16/2024Ownership: 0.068%Bayesian Capital Management LPBought 25,600 shares on 5/16/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price target for 2024? 7 brokers have issued 12 month target prices for Vir Biotechnology's shares. Their VIR share price targets range from $12.00 to $110.00. On average, they predict the company's share price to reach $33.57 in the next twelve months. This suggests a possible upside of 213.2% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2024? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has increased by 6.6% and is now trading at $10.72. View the best growth stocks for 2024 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.51. The company earned $56.38 million during the quarter, compared to analysts' expectations of $11.71 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 32.58% and a negative net margin of 677.69%. Vir Biotechnology's revenue was down 10.5% on a year-over-year basis. During the same period last year, the business posted ($1.06) EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Health Care ETF (PSCH).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.20%), Baillie Gifford & Co. (2.93%), Principal Financial Group Inc. (0.34%), Empowered Funds LLC (0.34%), Jacobs Levy Equity Management Inc. (0.23%) and Nordea Investment Management AB (0.18%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.